It was reported that the cardiac resynchronization therapy defibrillator (crt-0) system was suspected of exhibiting oversensing.Boston scientific technical services (ts) was consulted and reviewed several episodes in which t-wave oversensing was noted, and noise was observed.Ts discussed possible programming options, and will continue to monitor the patient.The crt-0 system remains in service.No adverse patient effects were reported.This report reflects information received by fda in the form of a notification per 803.22 (b)(2).
|